Cargando…

Idiopathic pulmonary fibrosis : advances in diagnostic tools and disease management /

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disea...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Nakamura, Hiroyuki (Editor ), Aoshiba, Kazutetsu (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Tokyo : Springer, [2016]
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 EBOOKCENTRAL_ocn922581492
003 OCoLC
005 20240329122006.0
006 m o d
007 cr cnu|||unuuu
008 150930s2016 ja ob 000 0 eng d
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d N$T  |d IDEBK  |d OCLCF  |d YDXCP  |d EBLCP  |d NUI  |d COO  |d GW5XE  |d KSU  |d IAD  |d JBG  |d ICW  |d VT2  |d Z5A  |d ILO  |d ICN  |d OCLCQ  |d ESU  |d IOG  |d CASUM  |d MERER  |d OCLCO  |d OCLCA  |d U3W  |d REB  |d WYU  |d OCLCO  |d OCLCA  |d UKMGB  |d AU@  |d OCLCQ  |d OCLCO  |d DCT  |d ERF  |d LEATE  |d OCLCQ  |d OCLCA  |d OCLCQ  |d AJS  |d OCLCQ  |d OCLCO  |d NLW  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCL 
015 |a GBB959735  |2 bnb 
016 7 |a 019320962  |2 Uk 
019 |a 922917801  |a 931592858  |a 932333581  |a 985042732  |a 1005791003  |a 1010741444  |a 1011790844  |a 1026456939  |a 1048134331  |a 1066612989  |a 1086569361  |a 1110762291  |a 1112544714  |a 1115971784  |a 1122848066  |a 1162795702 
020 |a 9784431555827  |q (electronic bk.) 
020 |a 443155582X  |q (electronic bk.) 
020 |z 9784431555810 
020 |z 4431555811 
024 7 |a 10.1007/978-4-431-55582-7  |2 doi 
029 1 |a AU@  |b 000056990620 
029 1 |a DKDLA  |b 820120-katalog:999895379505765 
029 1 |a UKMGB  |b 019320962 
035 |a (OCoLC)922581492  |z (OCoLC)922917801  |z (OCoLC)931592858  |z (OCoLC)932333581  |z (OCoLC)985042732  |z (OCoLC)1005791003  |z (OCoLC)1010741444  |z (OCoLC)1011790844  |z (OCoLC)1026456939  |z (OCoLC)1048134331  |z (OCoLC)1066612989  |z (OCoLC)1086569361  |z (OCoLC)1110762291  |z (OCoLC)1112544714  |z (OCoLC)1115971784  |z (OCoLC)1122848066  |z (OCoLC)1162795702 
037 |a com.springer.onix.9784431555827  |b Springer Nature 
050 4 |a RC776.F5 
060 4 |a WF 600 
072 7 |a HEA  |x 039000  |2 bisacsh 
072 7 |a MED  |x 014000  |2 bisacsh 
072 7 |a MED  |x 022000  |2 bisacsh 
072 7 |a MED  |x 112000  |2 bisacsh 
072 7 |a MED  |x 045000  |2 bisacsh 
072 7 |a MJL  |2 bicssc 
082 0 4 |a 616.2/4  |2 23 
049 |a UAMI 
245 0 0 |a Idiopathic pulmonary fibrosis :  |b advances in diagnostic tools and disease management /  |c Hiroyuki Nakamura and Kazutetsu Aoshiba, editors. 
264 1 |a Tokyo :  |b Springer,  |c [2016] 
264 4 |c Ã2016 
300 |a 1 online resource 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file 
347 |b PDF 
588 0 |a Online resource; title from PDF title page (EBSCO, viewed October 2, 2015). 
504 |a Includes bibliographical references. 
505 0 |a Preface; References; Contents; Part I: Definition, Epidemiology, and Pathogenesis; Chapter 1: Definition of IPF; 1.1 Introduction; 1.2 The ATS/ERS/JRS/ALAT 2011 Revised Diagnostic Criteria [5]; 1.3 Clinical Application and Key Problems; 1.4 Conclusion; References; Chapter 2: Epidemiology and Risk Factors of IPF; 2.1 Introduction; 2.2 Incidence and Prevalence; 2.2.1 In the USA; 2.2.2 In Europe; 2.2.3 In Japan; 2.3 Potential Risk Factors; 2.3.1 Smoking; 2.3.2 Inhalational Exposures; 2.3.3 Viral Infection; 2.3.4 Herpesviruses; 2.3.5 Hepatitis C Virus; 2.3.6 Gastroesophageal Reflux 
505 8 |a 2.3.7 Diabetes Mellitus2.4 Genetic Factors; 2.4.1 Familial Interstitial Pneumonia (FIP); 2.4.2 ELMOD2; 2.4.3 Surfactant Protein; 2.4.4 Telomerase; 2.4.5 MUC5B; 2.5 Conclusions; References; Chapter 3: Acute Exacerbation of IPF; 3.1 Introduction; 3.2 Definition; 3.3 Pathophysiology; 3.4 Trigger Factors; 3.5 Epidemiology; 3.6 Histopathology; 3.7 Radiological Assessment; 3.8 Laboratory Tests and Biomarkers; 3.9 Pharmacological Treatments; 3.10 Therapy with Polymyxin B-Immobilized Fiber Column; 3.11 Prevention; 3.12 Conclusions; References; Chapter 4: Pathogenesis of IPF 
505 8 |a 4.1 Hypothesis of the Molecular Pathogenesis of IPF: From Inflammation to Epithelial Injury4.2 Epithelial Injury and Genetic Background; 4.3 Biological Alteration in Injured AEC in IPF; 4.4 Critical Roles of Growth Factors in the Progression of Pulmonary Fibrosis; 4.4.1 PDGF and PDGF Receptors; 4.4.2 FGF and FGF Receptors; 4.4.3 VEGF and VEGF Receptors; 4.4.4 TGF-beta and TGF-beta Receptors; 4.4.5 Origin of Lung Fibroblasts and Their Contribution to Pulmonary Fibrosis; 4.4.6 Loss of Alveolar Epithelial Integrity and Pulmonary Fibrosis; 4.4.7 Resolution of ECM and Fibrosis; 4.4.8 Conclusions 
505 8 |a 5.7 Relation Between HRCT Findings and Biomarkers5.8 Mechanism and Significance for Dissociation Among Serum Biomarker Levels; 5.9 Biomarkers for IPF Other Than SP-A, SP-D, and KL-6; 5.10 Conclusion; References; Chapter 6: High-Resolution Computed Tomography of Honeycombing and IPF/UIP; 6.1 Introduction; 6.2 Honeycomb Lung (Honeycombing); 6.2.1 Definition of Honeycomb Lung; 6.2.2 Disagreement Among Radiologists in Judging Honeycomb Lung; 6.3 Imaging Findings of Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia; 6.3.1 Pathologic Criteria of IPF/UIP; 6.3.2 HRCT Criteria of IPF/UIP 
520 |a From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Pulmonary fibrosis. 
650 2 |a Idiopathic Pulmonary Fibrosis 
650 2 |a Pulmonary Fibrosis 
650 6 |a Fibrose pulmonaire. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x General.  |2 bisacsh 
650 7 |a MEDICAL  |x Clinical Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Diseases.  |2 bisacsh 
650 7 |a MEDICAL  |x Evidence-Based Medicine.  |2 bisacsh 
650 7 |a MEDICAL  |x Internal Medicine.  |2 bisacsh 
650 7 |a Pulmonary fibrosis  |2 fast 
655 4 |a Internet Resources. 
700 1 |a Nakamura, Hiroyuki,  |e editor. 
700 1 |a Aoshiba, Kazutetsu,  |e editor. 
758 |i has work:  |a Idiopathic pulmonary fibrosis (Text)  |1 https://id.oclc.org/worldcat/entity/E39PCYWBBqmVdmtmQwyWrpwmcX  |4 https://id.oclc.org/worldcat/ontology/hasWork 
776 0 8 |i Print version:  |t Idiopathic pulmonary fibrosis.  |d Tokyo : Springer, [2016]  |z 9784431555810  |z 4431555811  |w (OCoLC)911068522 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4178997  |z Texto completo 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL4178997 
938 |a EBSCOhost  |b EBSC  |n 1074271 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n cis32798974 
938 |a YBP Library Services  |b YANK  |n 12624192 
994 |a 92  |b IZTAP